New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
07:47 EDTJEC, PFEJacobs Engineering announces collaboration with Pfizer
Jacobs Engineering Group (JEC) announced a collaboration with Pfizer (PFE) on a modular process system to address the rapidly changing requirements of localized pharmaceutical manufacturing in emerging market countries. The collaboration brings together Pfizer’s aseptic drug product process expertise and Jacobs’ capabilities in modular engineering, fabrication, and testing to create a Rapid Deployment Module that integrates modular equipment, fully-automated control systems and single-use technology for bags, mixers, sterile connectors, manifolds and filters. The production systems are currently in their final stages of validation at a number of local pharmaceutical manufacturing sites around the world.
News For JEC;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
08:08 EDTPFEPfizer begins phase 2b study of Staphylococcus aureus vaccine
Subscribe for More Information
July 2, 2015
18:37 EDTPFEViiV, Desano enter strategic manufacturing agreement for Tivicay
Subscribe for More Information
16:37 EDTPFEPfizer announces FDA acceptance for review of NDA for Xeljanz
Subscribe for More Information
09:31 EDTPFEXRpro Sciences acquires assets related to ion channel platform from Pfizer
XRpro Sciences announced its acquisition of assets related to the ion channel biology platform from Pfizer that had previously been obtained as part of Pfizer's 2011 acquisition of Icagen. XRPro Sciences also acquired all of Pfizer's rights to the "Icagen" name and trademark. XRPro Sciences is re-launching the Icagen brand and will provide comprehensive services for ion channel and transporter drug discovery, combining Icagen's industry-leading scientific expertise and extensive portfolio of assays and cell lines with XRpro Sciences' proprietary, label-free X-ray fluorescence technology. The new Icagen will continue to operate out of the existing facility in Research Triangle Park, North Carolina in addition to the current XRpro Sciences Inc. site in Cambridge, Massachusetts. Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen, ensuring continuity of their extensive scientific expertise.
July 1, 2015
16:00 EDTPFEOptions Update; July 1, 2015
Subscribe for More Information
June 30, 2015
08:02 EDTJECJacobs Engineering in Joint Venture for Melbourne metro rail project contract
Subscribe for More Information
June 24, 2015
13:23 EDTPFEPfizer says CDC committee votes to recommend MenB vaccine
Pfizer announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers. It added, "Specifically, the ACIP voted that a serogroup B meningococcal vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age." Pfizer's Trumenba is FDA-approved for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. The ACIP recommendation will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval, Pfizer said.
11:02 EDTPFEPfizer lung cancer treatment granted FDA orphan drug designation
Subscribe for More Information
09:07 EDTPFECAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
June 23, 2015
14:17 EDTPFEGlycoMimetics to receive $20M payment from Pfizer
Subscribe for More Information
14:01 EDTPFEPfizer announces enrollment of first patient in RESET study
Subscribe for More Information
09:53 EDTPFEPfizer management to meet with FBN Securities
Meeting to be held in New York on June 25 hosted by FBN Securities.
07:48 EDTJECJacobs renews Project Representative role for Crossrail
Jacobs Engineering announced it was reappointed as Project Representative for the $22B, or GBP14.8B, Crossrail program by the U.K.'s Department for Transport and Transport for London. Company officials did not disclose the contract value, but noted that the contract is renewed for a term of up to five years. Under the terms of the contract, as Crossrail Project Representative, Jacobs is providing assurance to the project sponsors that Crossrail Ltd and its delivery partners deliver the project on schedule, within budget and to the agreed specification. This work involves a review of the program fundamentals: scope, strategy, risk, schedule, quality, cost and safety. It also considers the changing nature of Crossrail as it transitions from civil engineering to systems implementation and operations testing and commissioning.
07:46 EDTJECJacobs Engineering unit awarded contract by DECC
Subscribe for More Information
07:25 EDTPFEPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use